ICU Medical Dirección

Dirección controles de criterios 3/4

El CEO de ICU Medical's es Vivek Jain , nombrado en Feb 2014, tiene una permanencia de 10.17 años. compensación anual total es $6.81M, compuesta por 11.4% salario y 88.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.79% de las acciones de la empresa, por valor de $18.27M. La antigüedad media del equipo directivo y de la junta directiva es de 6.3 años y 7.3 años, respectivamente.

Información clave

Vivek Jain

Chief Executive Officer (CEO)

US$6.8m

Compensación total

Porcentaje del salario del CEO	11.4%
Permanencia del CEO	10.3yrs
Participación del CEO	0.8%
Permanencia media de la dirección	6.3yrs
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

Why Investors Shouldn't Be Surprised By ICU Medical, Inc.'s (NASDAQ:ICUI) Low P/S

Apr 26

ICU Medical (NASDAQ:ICUI) Takes On Some Risk With Its Use Of Debt

Mar 31

Is ICU Medical, Inc. (NASDAQ:ICUI) Trading At A 44% Discount?

Jan 31

ICU Medical, Inc.'s (NASDAQ:ICUI) Shares Lagging The Industry But So Is The Business

Jan 04

These 4 Measures Indicate That ICU Medical (NASDAQ:ICUI) Is Using Debt Extensively

Oct 28

Is There An Opportunity With ICU Medical, Inc.'s (NASDAQ:ICUI) 37% Undervaluation?

Oct 07

ICU Medical Non-GAAP EPS of $1.37 misses by $0.29, revenue of $561M misses by $3.1M

Aug 08

FDA labels ICU Medical unit's April recall of syringe infusion pumps as most serious

Jul 20

ICU Medical (NASDAQ:ICUI) Takes On Some Risk With Its Use Of Debt

Jun 08

ICU Medical: There Is Still Upside Here As Management Goes Big To Drive Value

Mar 25

A Look At The Intrinsic Value Of ICU Medical, Inc. (NASDAQ:ICUI)

Feb 23

Analysts Just Made A Significant Upgrade To Their ICU Medical, Inc. (NASDAQ:ICUI) Forecasts

Jan 28

Is Now The Time To Put ICU Medical (NASDAQ:ICUI) On Your Watchlist?

Dec 05

A Look At The Intrinsic Value Of ICU Medical, Inc. (NASDAQ:ICUI)

Nov 04

ICU Medical: Decisive M&A, Again

Sep 10

Is Now The Time To Put ICU Medical (NASDAQ:ICUI) On Your Watchlist?

Sep 05

Some Investors May Be Worried About ICU Medical's (NASDAQ:ICUI) Returns On Capital

Jul 30

Calculating The Intrinsic Value Of ICU Medical, Inc. (NASDAQ:ICUI)

Jun 27

Here's Why I Think ICU Medical (NASDAQ:ICUI) Is An Interesting Stock

May 28

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Vivek Jain en comparación con los beneficios de ICU Medical?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$7m	US$775k	-US$30m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$6m	US$756k	-US$74m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	US$5m
Mar 31 2022	n/a	n/a	US$41m
Dec 31 2021	US$5m	US$650k	US$103m
Sep 30 2021	n/a	n/a	US$109m
Jun 30 2021	n/a	n/a	US$103m
Mar 31 2021	n/a	n/a	US$94m
Dec 31 2020	US$3m	US$650k	US$87m
Sep 30 2020	n/a	n/a	US$81m
Jun 30 2020	n/a	n/a	US$83m
Mar 31 2020	n/a	n/a	US$87m
Dec 31 2019	US$3m	US$650k	US$101m
Sep 30 2019	n/a	n/a	US$73m
Jun 30 2019	n/a	n/a	US$47m
Mar 31 2019	n/a	n/a	US$55m
Dec 31 2018	US$6m	US$650k	US$29m
Sep 30 2018	n/a	n/a	US$86m
Jun 30 2018	n/a	n/a	US$86m
Mar 31 2018	n/a	n/a	US$18m
Dec 31 2017	US$4m	US$650k	US$69m

Compensación vs. Mercado: La compensación total ($USD6.81M) de Vivek está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.61M).

Compensación vs. Ingresos: La compensación de Vivek ha aumentado mientras la empresa no es rentable.

CEO

Vivek Jain (51 yo)

10.3yrs

Permanencia

US$6,810,975

Compensación

Mr. Vivek Jain has been an Independent Director of Envista Holdings Corporation since April 07, 2020. Mr. Jain has been Chairman and Chief Executive Officer of ICU Medical, Inc. since February 13, 2014. Mr...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Vivek Jain	CEO & Chairman of the Board	10.3yrs	US$6.81m	0.79% $ 19.0m
Brian Bonnell	CFO & Treasurer	4.2yrs	US$4.39m	0.10% $ 2.5m
Christian Voigtlander	Chief Operating Officer	6.3yrs	US$4.40m	0.051% $ 1.2m
Virginia Sanzone	Corporate VP	6.3yrs	US$2.47m	0.027% $ 642.1k

6.3yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ICUI es experimentado (6.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Vivek Jain	CEO & Chairman of the Board	10.3yrs	US$6.81m	0.79% $ 19.0m
Elisha Finney	Independent Director	8.3yrs	US$265.14k	0.0061% $ 145.6k
George Lopez	Director	40.3yrs	sin datos	4.9% $ 117.5m
Kolleen Kennedy	Independent Director	2.4yrs	US$255.14k	0.0025% $ 60.4k
David Hoffmeister	Independent Director	6.3yrs	US$282.14k	0.0085% $ 204.3k
Laurie Hernandez	Independent Director	2.8yrs	US$255.14k	0.0039% $ 92.2k
David Greenberg	Lead Independent Director	8.8yrs	US$296.14k	0.019% $ 450.9k
Donald Abbey	Independent Director	6.3yrs	US$255.14k	0.0085% $ 204.3k

7.3yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de ICUI se considera experimentada (7.3 años de antigüedad promedio).

ICU Medical Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

ICU Medical, Inc., Annual General Meeting, May 15, 2024

CEO & Chairman of the Board exercised options and sold US$262k worth of stock

ICU Medical, Inc. Announces the Resignation of Bill Seeger as Nominated Director

Director notifies of intention to sell stock

Chief Operating Officer recently sold US$1.5m worth of stock

ICU Medical, Inc. Announces Resignation of William Seeger from Board of Director and Member of the Audit and Compliance Committee

Recent updates

Why Investors Shouldn't Be Surprised By ICU Medical, Inc.'s (NASDAQ:ICUI) Low P/S

ICU Medical, Inc. to Report Q1, 2024 Results on May 07, 2024

ICU Medical, Inc., Annual General Meeting, May 15, 2024

ICU Medical (NASDAQ:ICUI) Takes On Some Risk With Its Use Of Debt

CEO & Chairman of the Board exercised options and sold US$262k worth of stock

ICU Medical, Inc. Announces the Resignation of Bill Seeger as Nominated Director

Director notifies of intention to sell stock

Chief Operating Officer recently sold US$1.5m worth of stock

ICU Medical, Inc. Announces Resignation of William Seeger from Board of Director and Member of the Audit and Compliance Committee

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO & Chairman of the Board exercised options and sold US$5.4m worth of stock

ICU Medical, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Is ICU Medical, Inc. (NASDAQ:ICUI) Trading At A 44% Discount?

ICU Medical, Inc.'s (NASDAQ:ICUI) Shares Lagging The Industry But So Is The Business

ICU Medical, Inc.(NasdaqGS:ICUI) dropped from S&P 400 Health Care (Sector)

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 24% to US$154

These 4 Measures Indicate That ICU Medical (NASDAQ:ICUI) Is Using Debt Extensively

ICU Medical, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Is There An Opportunity With ICU Medical, Inc.'s (NASDAQ:ICUI) 37% Undervaluation?

Chief Operating Officer recently sold US$884k worth of stock

Chief Operating Officer notifies of intention to sell stock

ICU Medical Inc. Receives FDA Clearance for Plum Duo Infusion Pump and LifeShield Infusion Safety Software

Icu Medical, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ICU Medical, Inc. to Report Q2, 2023 Results on Aug 07, 2023

ICU Medical (NASDAQ:ICUI) Takes On Some Risk With Its Use Of Debt

Now 23% undervalued after recent price drop

CEO & Chairman of the Board notifies of intention to sell stock

ICU Medical, Inc.(NasdaqGS:ICUI) dropped from Russell Small Cap Comp Growth Index

Calculating The Intrinsic Value Of ICU Medical, Inc. (NASDAQ:ICUI)

CEO & Chairman of the Board exercised options and sold US$3.9m worth of stock

First quarter 2023 earnings: EPS misses analyst expectations

Corporate VP notifies of intention to sell stock

Here's Why ICU Medical (NASDAQ:ICUI) Can Afford Some Debt

CEO & Chairman of the Board exercised options and sold US$1.5m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Estimating The Intrinsic Value Of ICU Medical, Inc. (NASDAQ:ICUI)

ICU Medical, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ICU Medical (NASDAQ:ICUI) Takes On Some Risk With Its Use Of Debt

Corporate VP notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

ICU Medical, Inc. Reaffirms Earnings Guidance for the Full Year 2022

ICU Medical, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Director exercised options to buy US$12m worth of stock.

ICU Medical (NASDAQ:ICUI) Takes On Some Risk With Its Use Of Debt

ICU Medical Hit Hard As Smiths Medical Needs Significant TLC

Consensus EPS estimates fall by 326%

Price target decreased to US$221

ICU Medical Non-GAAP EPS of $1.37 misses by $0.29, revenue of $561M misses by $3.1M

Consensus forecasts updated

FDA labels ICU Medical unit's April recall of syringe infusion pumps as most serious

ICU Medical, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Consensus EPS estimates fall by 18%

ICU Medical (NASDAQ:ICUI) Takes On Some Risk With Its Use Of Debt

Consensus EPS estimates fall by 50%

Corporate VP recently sold US$130k worth of stock

Now 21% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ICU Medical, Inc. to Report Q1, 2022 Results on May 09, 2022

ICU Medical, Inc., Annual General Meeting, May 17, 2022

ICU Medical: There Is Still Upside Here As Management Goes Big To Drive Value

CEO & Chairman of the Board exercised options and sold US$411k worth of stock

CEO & Chairman of the Board exercised options and sold US$6.5m worth of stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

ICU Medical, Inc. Provides Earnings Guidance for the Fiscal Year 2022

A Look At The Intrinsic Value Of ICU Medical, Inc. (NASDAQ:ICUI)

ICU Medical, Inc. Announces Executive changes, Effective March 18, 2022

Price target decreased to US$260